# Bosentan in Digital Ulcers

> **NCT00319696** · PHASE3 · COMPLETED · sponsor: **Actelion** · enrollment: 116 (actual)

## Conditions studied

- Digital Ulcers

## Interventions

- **DRUG:** Bosentan 62.5 mg
- **DRUG:** Bosentan 125 mg

## Key facts

- **NCT ID:** NCT00319696
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07-08
- **Primary completion:** 2009-01-22
- **Final completion:** 2009-01-22
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00319696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00319696, "Bosentan in Digital Ulcers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00319696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*